clinical trial · NCT03885037
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)
Pfizer·—·completed·n = 77
Rheumatoid ArthritisInfliximab [infliximab biosimilar 3]
brief summary
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against rheumatoid arthritis under actual status of use.
started
Mar 20, 2019
primary completion
Nov 29, 2024
completion
Nov 29, 2024
last updated
Jan 6, 2026
official title
Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" General Investigation (Rheumatoid Arthritis)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol